CS
MLYS icon

Candriam SCA’s Mineralys Therapeutics MLYS Stock Holding History

Candriam SCA’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.7M Buy
801,904
+123,517
+18% +$3.62M 0.11% 181
2025
Q4 		$24.6M Buy
678,387
+110,606
+19% +$4.44M 0.12% 167
2025
Q3 		$21.5M Sell
567,781
-256,406
-31% -$5.55M 0.11% 175
2025
Q2 		$11.2M Sell
824,187
-58,646
-7% -$850K 0.06% 233
2025
Q1 		$14M Buy
882,833
+577,561
+189% +$6.64M 0.09% 202
2024
Q4 		$3.76M Buy
+305,272
New +$3.99M 0.02% 397

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Candriam SCA's MLYS Position: Q1 2026 in Review

Candriam SCA increased its Mineralys Therapeutics (MLYS) stake by 18% in Q1 2026, buying an estimated $3.62M and bringing the position to 801,904 shares worth $21.7M. The position accounts for 0.11% of the portfolio, ranked #181.

Candriam SCA first reported a position in MLYS in Q4 2024 and has held it in 6 quarters since. The position peaked at $24.6M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Candriam SCA held 801,904 shares of Mineralys Therapeutics worth $21.7M as of Q1 2026.
  • Candriam SCA bought 123,517 Mineralys Therapeutics shares in Q1 2026, an estimated $3.62M.
  • Mineralys Therapeutics made up 0.11% of Candriam SCA's portfolio in Q1 2026, its #181 holding.
  • Candriam SCA first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Candriam SCA's Mineralys Therapeutics position peaked at $24.6M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.